Fentanyl Identification On the Street and In the Lab

Cybin Announces the Development of a Scalable Psychedelic Facilitation Training Program, EMBARKCT | Psychedelic Finance

Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) (“Cybin” or the “Company”), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative psychedelic-based treatment

July 13, 2023

Will a government shutdown stall Medicare drug price negotiations?

You’re reading the web edition of D.C. Diagnosis. Sign up here to receive this newsletter in your inbox on Tuesdays and Thursdays. Does the shutdown actually stall

September 26, 2023

NewAmsterdam aces Phase 3 trial, but investors are skeptical

NewAmsterdam Pharma’s lead cardio program obicetrapib passed another Phase 3 trial, demonstrating its ability to lower “bad cholesterol” in combination with a drug called ezetimibe

November 21, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.